GHK-Cu Research: The Copper Tripeptide and What Studies Have Investigated
GHK-Cu research is the study of a small copper-binding tripeptide. This page summarises what GHK-Cu is, its copper-complex chemistry, the mechanisms researchers have examined, and the gene-expression profiling in the literature — cited neutrally, framed as “studies investigated,” with much of the evidence in vitro, computational, or animal-model. No efficacy or cosmetic claims.
What is GHK-Cu?
What is GHK-Cu? It is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine — three amino acids, Gly-His-Lys, bound in a 1:1 complex to a single copper(II) ion. The GHK tripeptide is a molecule found endogenously in human plasma, saliva and urine, and its measured level is reported to decline with age. That age-related decline is a descriptive observation in the literature; it is stated here as background chemistry and biology, not as a reason to use the compound.
Discovery and origin in the literature
Isolation from human plasma (1973)
GHK was first isolated by Pickart and Thaler (1973), who identified an albumin-bound activity in human serum that, in cell culture, made aged liver tissue synthesise protein in a manner resembling younger tissue. Framed accurately, this was an observation about behaviour in cell culture — the historical starting point of the field, not a benefit.
The copper-transport hypothesis
Subsequent work in the 1980s proposed that GHK functions in part by facilitating copper uptake into cells — the “copper-transport” hypothesis. The neutral phrasing that the literature itself uses is that researchers proposed this role; it is a mechanistic hypothesis under study rather than an established function.
Molecule and copper-complex properties
The peptide is the sequence Gly-L-His-L-Lys; the copper complex adds a coordinated Cu(II) ion, so the peptide and the copper complex have distinct molecular formulae and weights. In research catalogues the material is supplied as a lyophilized powder and characterised in that form.
How GHK binds copper(II)
The coordination chemistry is well described: theoretical and crystallographic binding studies report that copper(II) is held by the N-terminal amine of glycine, the deprotonated peptide nitrogen of the Gly-His bond, and the imidazole nitrogen of histidine, forming a square-planar (or square-pyramidal) Cu(II) geometry. The reported affinity constant is high — log K ≈ 16.2–16.4 — which the literature characterises as “high enough to hold copper in circulation, low enough to exchange with higher-affinity targets.” These are descriptive coordination-chemistry facts.
Mechanisms researchers have examined
GHK-Cu is described in the literature as pleiotropic — no single receptor target. The examined mechanisms, each framed as what in-vitro and animal-model studies investigated:
- Matrix remodeling — modulation of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs), and studied stimulation of collagen, elastin and glycosaminoglycan (dermatan sulfate, chondroitin sulfate, decorin) synthesis in fibroblast models (Pickart et al., 2008; 2015).
- Fibroblast behaviour — examined fibroblast proliferation and function in culture.
- Growth factors / angiogenesis — studies examined VEGF and bFGF expression and capillary sprouting in model systems.
- Anti-inflammatory / antioxidant pathways — the copper complex was examined for effects on TNF-α-induced IL-6 secretion in dermal fibroblasts and for antioxidant-response gene sets (Pickart & Margolina, 2012).
Each bullet names a research direction examined in models, not an outcome. Because the observations span several pathways rather than one defined target, the field describes the molecule as pleiotropic — a description, not a benefit claim.
Gene-expression research
A distinctive strand of the GHK literature is gene-expression profiling. Analyses using the Broad Institute Connectivity Map, referenced in Pickart et al. (2015) and Pickart & Margolina (2018), reported that GHK at nanomolar levels was associated with changed expression across a large set of human genes — with DNA-repair, antioxidant and tissue-remodeling sets reported up and certain other sets reported down. This is a computational screening observation: profiling reported associations, which is not the same as a demonstrated outcome. Additional profiling examined nervous-system-related gene expression (Pickart et al., 2017). The neutral framing throughout is “gene-expression profiling reported.”
Research models and evidence status
To be explicit about where the evidence sits: much of the body of work is in vitro (fibroblast and keratinocyte cultures), computational (gene-expression screens), and animal-model; controlled human clinical data is limited. GHK-Cu sits within a broader copper-peptide literature as one well-studied example, and this page offers no verdict on efficacy — only a neutral summary of what has been investigated.
How GHK-Cu relates to the copper-peptide and skin-research group
GHK-Cu is the single-molecule counterpart to the GLOW research blend, which includes GHK-Cu among other peptides — a separate preparation covered by its own explainer. It is also one of several copper tripeptides that appear in the research literature (for example AHK-Cu), named here as research context rather than a comparison of results. This is positioning by research focus only, not stacking or combination advice.
Research-grade sourcing and verification
For laboratory research use only, GHK-Cu is supplied with a per-batch Certificate of Analysis reporting HPLC purity (%) and mass-spec identity confirmation, with third-party testing. Identity and purity matter especially for a copper complex, where copper content and stoichiometry are part of a reproducible material. The exact batch received can be checked on the self-serve verify tool, and how to read a COA explains each line of the certificate.
Verify a batch
Every order ships with a per-batch Certificate of Analysis. Have a vial in hand? Enter its lot number to look up the COA for that exact batch.
Frequently asked questions
What is GHK-Cu?
Is GHK-Cu naturally occurring?
How does GHK bind copper?
What has gene-expression research reported about GHK?
Is GHK-Cu the same as the GLOW blend?
Literature cited
- Pickart L, Thaler MM. “A tripeptide in human serum that stimulates growth/survival of hepatoma and normal liver cells” (isolation of GHK). 1973.
- Pickart L, Vasquez-Soltero JM, Margolina A. “GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration.” BioMed Research International. 2015 (PMC4508379).
- Pickart L, Margolina A. “Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.” Int. J. Molecular Sciences. 2018 (PMID 29986520).
- Pickart L, Margolina A. “The Human Tripeptide GHK-Cu in Prevention of Oxidative Stress and Degenerative Conditions of Aging.” Oxidative Medicine and Cellular Longevity. 2012 (PMC3359723).
- Pickart L, Vasquez-Soltero JM, Margolina A. “The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline.” 2017 (PMC5332963).
- Pickart L, et al. “The human tri-peptide GHK and tissue remodeling.” J. Biomaterials Science, Polymer Edition. 2008 (PMID 18644225).
- Borkow G. “Using Copper to Improve the Well-Being of the Skin.” Current Chemical Biology. 2014 (PMC4556990).
- “Theoretical study of copper binding to GHK peptide.” Computational Biology and Chemistry. 2020 — square-planar coordination and affinity-constant statements.
RESEARCH USE ONLY — NOT FOR HUMAN CONSUMPTION. All products are sold strictly for in-vitro laboratory research and are not intended for human or veterinary use, ingestion, or administration. Nothing on this page is a medical or efficacy claim. You must be 21 or older to browse this catalog.